ENT1 Inhibitors
Items 1 to 10 of 14 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Dipyridamole | 58-32-2 | sc-200717 sc-200717A | 1 g 5 g | $31.00 $102.00 | 1 | |
Dipyridamole is a unique compound that functions as an inhibitor of adenosine uptake, engaging in specific interactions with nucleoside transporters. Its dual-ring structure allows for effective π-π stacking with aromatic residues, enhancing binding affinity. The compound exhibits complex reaction kinetics, characterized by a slow dissociation rate, which prolongs its effects on cellular signaling pathways. Additionally, its hydrophilic nature influences solubility and distribution in biological systems. | ||||||
S-(4-Nitrobenzyl)-6-thioinosine (NBTI, NBMPR) | 38048-32-7 | sc-200117 | 50 mg | $163.00 | 1 | |
S-(4-Nitrobenzyl)-6-thioinosine (NBTI) is a selective inhibitor of nucleoside transporters, characterized by its unique thioinosine moiety that enhances binding through sulfur interactions. The nitrobenzyl group facilitates strong π-π interactions with aromatic amino acids, promoting specificity. NBTI exhibits distinct reaction kinetics, with a notable affinity for the transporter, leading to prolonged inhibition. Its lipophilic properties influence membrane permeability, affecting cellular uptake dynamics. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that specifically targets the BCR-ABL fusion protein, inhibiting aberrant signaling pathways in chronic myeloid leukemia (CML) cells. | ||||||
MDV3100 | 915087-33-1 | sc-364354 sc-364354A | 5 mg 50 mg | $245.00 $1051.00 | 7 | |
Enzalutamide inhibits the androgen receptor (AR) by binding to it and preventing its activation, suppressing AR-mediated transcription and growth of prostate cancer cells. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an epidermal growth factor receptor (EGFR) inhibitor, blocking EGFR tyrosine kinase activity to halt signaling in lung cancer cells with EGFR mutations. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multi-kinase inhibitor that inhibits the RAF/MEK/ERK pathway, reducing cell proliferation and angiogenesis in liver and kidney cancers. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
Vemurafenib selectively targets mutated BRAF kinases in melanomas, inhibiting their activity and preventing downstream signaling in cancer cells. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib is a dual tyrosine kinase inhibitor targeting EGFR and HER2, inhibiting their phosphorylation and blocking signaling in breast and gastric cancers. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that disrupts B-cell receptor signaling, leading to apoptosis and reducing the growth of B-cell malignancies. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib inhibits the proteasome, preventing protein degradation and causing apoptosis in multiple myeloma cells and some lymphomas. | ||||||